TRAITEMENT DU DIABETE

Patent europeic · EP0762890 · Stritgà

Inscripziun en il register

Numer da publicaziun
EP0762890
Numer da la dumonda
EP95917874
Gener
Patent europeic cun effect per la Svizra ed il Liechtenstein
Status
Stritgà
Scrittira da patent
Concedì
Annunzià
12-05-1995
Publitgà
19-03-1997
Concedì
26-07-2000
Stritgà
26-07-2000
Motiv
Revocà en la procedura d’opposiziun
Classas IPC
A61K 38/26 (2006.01)
Prioritad
GB 9409496 12.05.1994
Dumonda PCT
PCT/CA1995/000287 12.05.1995
Publicaziun PCT
WO1995/031214 23.11.1995
Lingua da l’annunzia
englais
Funtauna
Swissreg

Istorgia

Quai che l’Institut federal da la proprietad intellectuala ha publitgà davart quest titel, il pli nov l’emprim.

  1. 25-06-2024

    Midada

    Published in Swissreg on 25.06.2024

  2. 25-06-2024

    Midada

    Published in Swissreg on 25.06.2024

  3. 14-01-2005

    Stritgà, taxa betg pajada

    Published in +pat+ No 1 in 2005

  4. 13-10-2000

    Represchentant inscrit

    Representative
    Patentanwälte, Schaad, Balass, Menzl & Partner AG, Dufourstrasse 101, 8034 Zürich

    Published in PIDTJ No 19 in 2000

  5. 31-07-2000

    Concedì

    Published in PIDTJ No 14 in 2000

Partidas

Possessur

Amylin Pharmaceuticals, Inc.

AMYLIN PHARMACEUTICALS, INC.

9373 Towne Centre Drive, San Diego, California 92121, US

Represchentant

Patentanwälte Schaad, Balass, Menzl & Partner AG

Dufourstrasse 101, 8034 Zürich

Inventur

DUPRE, John

London, Ontario N6A 2E2, CA

Il register numna mintga partida cun num ed adressa. In possessur u in represchentant vegn collià cun in’organisaziun, sch’exact ina unitad giuridica dal register da commerzi porta ses num; la via d’ina partida betg enconuschida uschia na vegn betg mussada qua.